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http://dx.doi.org/10.1016/j.kjms.201Abstract Hypoxia-inducible factor (HIF) plays an important role in renal cell carcinoma (RCC)
associated with angiogenesis. Factor-inhibiting HIF (FIH), which is the upstream mediator pro-
tein of HIF, is receiving more attention today. In the present study, the role of FIH expression in
high-risk locally advanced renal cell carcinoma (LARCC) was explored. Eighty-eight high-risk
LARCC cases were divided into two groups based on their prognosis. Using immunohistochem-
ical staining, the correlations of FIH expression along with clinicopathological factors,
progression-free survival (PFS), and overall survival (OS) were analyzed. FIH was mainly
located in the cytoplasm (34/88) and nucleus (31/88) of the renal tumor cell. Nuclear negative
expression or cytoplasmic positive expression of FIH were associated with an increased risk of
disease progression (p Z 0.007 and p < 0.001, respectively) and worse OS (p Z 0.020 and
p Z 0.008, respectively). Using the group with nuclear and cytoplasmic FIH negative expres-
sion as reference, further stratified analysis found that the exclusive nuclear FIH expression
group had a better PFS and OS [hazard ratio (HR) Z 0.153, p Z 0.07 and HR Z 0,
p Z 0.961, respectively], and the exclusive cytoplasmic FIH positive group experienced the
worst PFS and OS (HRZ 2.876, p Z 0.005 and HR Z 2.799, pZ 0.034, respectively). In addi-
tion, nuclear negative expression of FIH was associated with a significant negative predictive
value for the effect of interferon-alpha (IFN-a) on PFS (p Z 0.045). The nuclear negative and
cytoplasmic positive expressions of FIH were identified not only as risk factors for disease pro-
gression in high-risk LARCC postoperative patients, but also to be associated with poor OS.have no conflicts of interest relevant to this article.
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Renal cell carcinoma (RCC) accounts for 80% of the carci-
noma of the kidney and causes 102,000 deaths per year
[1,2]. Based on the current clinical stage, about 70% of
carcinoma patients can be diagnosed to have localized or
locally advanced renal cell carcinoma (LARCC). Similar to
other malignant tumors, surgical excision is usually
considered the first treatment option. After radical or
partial nephrectomy, nearly 20e40% of the cases with
no original evidence of metastases experience recur
rence and metastasis [3]. In the case of metastasis, the
prognosis is poor and the 2-year survival rate is 20% [4].
These data suggest the importance of accurate means
for forecasting tumor progression in individuals with
LARCC.
Currently, UISS (UCLA Integrated Staging System), (the
score based on stage, size, grade, and necrosis) SSIGN, and
Leibovich algorithm [5e7] are the widely used integrated
staging systems for predicting the outcome of patients
with clear cell renal cell carcinoma (ccRCC). However,
these systems are based on the tumor, lymph nodes, and
metastasis staging system (TNM) classification issued by
American Joint Committee on Cancer (AJCC) in 2002 [8].
Other variables, such as molecules, can also act as prog-
nostic factors for evaluating the recurrence or progression
of the disease. Examples of these include alfa-fetoprotein
(AFP) levels in hepatocellular carcinoma [9], prostate-
specific antigen (PSA) levels in prostate cancer [10], and
so on. Although several molecules, including Neutrophil
gelatinase-associated lipocalin (NGAL) [11], B7-H1 [12],
and vascular endothelial growth factor (VEGF) [13], have
been linked with the clinical outcomes of RCC, none of
them have been used in clinical decision making.
As the hub in the signaling pathways for angiogenesis in
solid tumorigenesis, VEGF is regulated by hypoxia-inducible
factor (HIF), which is a heterodimer composed of a and
b subunits [13,14]. The level of a subunit in a tumor dic-
tates HIF’s function. Currently, there are two mechanisms
that utilize it. Although the regulatory mechanisms are
different, prolyl hydroxylase domain enzymes (PHDs) and
factor-inhibiting hypoxia-inducible factor (FIH) act in
accordance with HIF-1a expression [15,16]. Notably, FIH
plays a more prominent role in inhibiting HIF-1a transcrip-
tional activity [17].
Recently, a report stated that low nuclear expression of
FIH is a strong independent prognostic factor for a poor
overall survival (OS) in ccRCC [18]. The Leibovich algorithm
is a prediction model to forecast the disease progression of
ccRCC, based on tumor stage, regional lymph node status,
tumor size, nuclear grade, and histologic tumor necrosis
[7]. Patients undergoing radical nephrectomy can be
stratified into three groups based on the risk for metastases
according to Leibovich scores, and patients belonging togroups with high scores ( 6) face greater risks than the
others [7]. This study explores whether FIH expression is a
useful factor in predicting high-risk LARCC progression after
surgical resection.
Materials and methods
Patients and follow-up
Under the ethical guidelines and after gaining informed
consent, pathological sections and associated clinical infor-
mation were prospectively collected from 88 patients with
RCC from 2001 to 2006. Patients with chromophobe RCC and
collecting system tumor other than ccRCC were excluded.
The median follow-up of the cohort was 59 months. Ac-
cording to the Leibovich integrated stratification system, all
the cases were regarded to be at high risk for progression.
Detailed follow-up data were available for all the pa-
tients. On the final cutoff day, a total of 39 patients had
disease progression and 21 patients died of cancer-related
diseases. Demographic, clinical, and pathological data on
age, sex, tumor site, primary size, TNM classification,
clinical staging, Fuhrman grading, tumor necrosis, Leibo-
vich score, and postoperative adjuvant therapy were
collected in detail. Progression-free survival (PFS) and OS
were the two final indicators in this study.
Immunohistochemical analysis
Immunohistochemical staining was performed using a
monoclonal antibody against FIH-1. Formalin-fixed, paraffin-
embedded tissue sections (4 mm) of microarrayed ccRCC
were dewaxed in xylene and then rehydrated in graduated
ethanol solutions. The endogenous peroxidase activity was
blocked with 3% hydrogen peroxide for 45 minutes. The pri-
mary antibodies, namely, FIH-1 antibody (clone FIH162c,
mouse IgG1 monoclonal antibody; ABCAM, Cambridge, MA,
USA), were incubated for 16e18 hours at 4 C. Phosphate-
buffered saline was used as a negative control, and breast
carcinoma tissue was used as a positive control.
Two pathologists, who were unaware of the relevant clin-
ical data, viewed and scored the FIH expression indepen-
dently. When the scores differed, disagreements were
adjudicated by a third observer. The percentage of positively
stained nuclei and cytoplasmic stainingwas assessed based on
a semiquantitative scoring system. The scoring system for the
percentage of stained nuclei was as follows: 0, <25% cells
staining positive; 1, 30e50% positive cells; and 2, >50% posi-
tive cells. The scoring system for nuclei and cytoplasmic
stainingwas the following: 0, negative; 1, weak; 2,moderate;
and 3, strong. Tumor cells expressing FIHwith intensity2 and
the percentage of stained nuclei 30% were defined as posi-
tive expressions.
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Data were analyzed using the SPSS 19.0 software package
(SPSS Inc., Chicago, IL, USA). The relationship between FIH
and clinicopathological factors was assessed with the Chi-
square test. KaplaneMeier survival curves were used to
analyze PFS and OS. Prognostic roles of the factors were
assessed by univariate and multivariate analyses using a
Cox regression model.Results
Tumor characteristics and immunohistochemical
staining of FIH
The relationship between clinicopathological parameters
and immunohistochemical staining of FIH is presented in
Table 1. FIH was mainly located in the nucleus, the cyto-
plasm, or both compartments, with patterns ranging from
extensive staining to focal or absent expression (Fig. 1). The
nucleus expression rate of FIH was 35.2% (31/88) and theTable 1 Clinicopathological parameters together with correlat
Characteristic Exclusive
nuclear FIHþ
(n Z 15)
Nuclear and
cytoplasmic
FIHþ (n Z 16)
Age (y)
60 7 8
<60 8 8
Sex
Male 6 11
Female 9 5
Origin
Left 9 8
Right 6 8
Tumor size (cm)
10 4 4
<10 11 12
Necrosis
Yes 10 7
No 5 9
T stage
T2 2 4
>T2 13 12
N stage
N or N0 10 12
N1 5 4
Fuhrman grade
2 4 3
3 11 11
4 0 2
Leibovich score
<6 4 7
6 11 9
IFN-a adjuvant therapy
Yes 4 7
No 11 9
FIH Z factor-inhibiting hypoxia-inducible factor; IFN-a Z interferon-cytoplasm expression rate was 38.6% (34/88). However, 17%
(15/88) of the tumors expressed FIH exclusively in the nu-
cleus, 20.1% (18/88) exclusively in the cytoplasm, and 18.2%
(16/88) in both the nucleus and the cytoplasm. FIH expres-
sion showed no correlation with age, sex, diameter of
tumor, T staging, N staging, clinical staging, tumor necrosis,
Leibovich scores, and Eastern Cooperative Oncology Group
(ECOG) performance status (data not shown).
FIH expression, clinicopathological characteristics,
and survival of patients with high-risk LARCC
During the follow-up periods, 44.3% (39/88) of patients
presented with distant metastasis, such as those in lung,
bone, lymph node, liver, and brain. However, FIH expression
was not associated with metastatic sites. Univariate analysis
demonstrated that patients with nuclear negative expres-
sion or positive cytoplasmic expression of FIH was associated
predominately with shorter PFS and OS time than those with
nuclear positive expression or cytoplasmic negative
expression (Fig. 2AeD). To minimize the confounding effect
caused by subcellular localization, 88 cases were dividedion analyses of cytoplasmic and nuclear FIH expressions.
Exclusive
cytoplasmic
FIHþ (n Z 18)
Nuclear and
cytoplasmic
FIH (n Z 39)
p
9 17 0.960
9 22
13 26 0.210
5 13
12 25 0.748
6 14
3 13 0.618
15 26
12 22 0.495
6 17
5 6 0.596
13 33
14 28 0.904
4 11
4 7 0.832
12 26
2 6
10 17 0.856
8 22
12 15 0.108
6 24
alpha.
Figure 1. Immunohistochemistry of FIH in high-risk locally advanced renal cell carcinoma [magnification: 400 (10  40)]: (A)
negative tumor staining; (B) positive nuclear staining; (C) positive cytoplasmic staining; and (D) both nuclear and cytoplasmic
positive staining. FIH Z factor-inhibiting hypoxia-inducible factor.
FIH expression in renal tumor 15into four groups: exclusive nuclear FIH expression, nuclear
and cytoplasmic FIH expression, exclusive cytoplasmic FIH
expression, and nuclear and cytoplasmic FIH negative
expression. Using the nuclear and cytoplasmic FIH negative
expression group as reference, further stratified analysis
found that the exclusive nuclear FIH expression group had a
better PFS and OS [hazard ratio (HR)Z 0.153, pZ 0.07 and
HR Z 0, p Z 0.961, respectively], and the exclusive cyto-
plasmic FIH positive group experienced the worst PFS and OS
(HR Z 2.876, p Z 0.005 and HR Z 2.799, p Z 0.034,
respectively) (Fig. 2EeF) Other clinicopathological param-
eters, including age, sex, tumor location, diameter of tumor,
tumor necrosis, TNM staging, and Leibovich scores, were
also evaluatedwith PFS or OS status. Regrettably, the results
showed no associations (Tables 2 and 3).
A multivariate analysis using Cox proportional hazard
regression showed that the nuclear negative expression or
positive cytoplasmic expression of FIH was an independent
prognostic factor not only for disease progression in pa-
tients with high risk of LARCC (p Z 0.007 and p < 0.001),
but also for OS (p Z 0.020 and p Z 0.008).
Relationship between FIH expression and
postoperative adjuvant therapy
Overall, 43.2% (38/88) of the patients received interferon-
alpha (IFN-a) as their postoperative adjuvant therapy.Compared with those who did not receive immunotherapy,
no differences in terms of mean PFS or OS time were
observed. A subgroup analysis for association of FIH with
patients who have received IFN-a showed that nuclear
negative expression of FIH was associated with a significant
negative predictive value for the effect of IFN-a on PFS
(p Z 0.045, Fig. 2G).
Discussion
Angiogenesis is one of the crucial steps in the survival,
malignant growth, and subsequent distant metastasis of
tumors [19]. When these malignant cells are accumulated
to a certain extent, the number of proliferating and dying
cells reaches a general state of dynamic counterbalance.
Therefore, from the macro view, the tumor stops growing
and maintains a steady state [20]. Compared with normal
conditions, the malignant tissue requires more nutrients.
The hypoxia status is ineluctable when no new blood vessels
are formed. Considering the existence of a series of pro-
tection mechanisms, the tumor can continue to survive in
such circumstances [21]. Although the molecular mecha-
nism involved in neovascularization under the chronic
hypoxic condition is not yet understood precisely, VEGF-A
may play a key role in this event [19]. Coordination of the
effects of HIF in an angiogenic mechanism has continued to
attract the attention of researchers in recent years. As a
Figure 2. KaplaneMeier curves of (A) PFS stratified by nuclear FIH expression in LARCC; (B) PFS stratified by cytoplasmic FIH
expression in LARCC; (C) OS stratified by nuclear FIH expression in LARCC; (D) OS stratified by cytoplasmic FIH expression in LARCC;
(E) PFS stratified by FIH subcellular localization in LARCC; (F) OS stratified by FIH subcellular localization in LARCC; and (G) PFS
stratified by nuclear FIH expression in IFN-a treatment. FIHZ factor-inhibiting hypoxia-inducible factor; IFN-aZ interferon-alpha;
LARCC Z locally advanced renal cell carcinoma; OS Z overall survival; PFS Z progression-free survival.
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Table 2 Univariate analysis of survival in patients with high-risk LARCC.
Grouping Cutoff value N OS p PFS p
(Log rank tests) (Log rank tests)
Age (y) 60 41 13/41 0.292 20/41 0.571
<60 47 9/47 19/47
Sex Male 56 15/56 0.810 27/56 0.641
Female 32 7/32 12/32
Origin Left 54 13/54 0.846 23/54 0.838
Right 34 9/34 16/34
Tumor size (cm) <10 64 17/64 0.695 26/64 0.280
10 24 5/24 13/24
Necrosis No 37 12/37 0.173 17/37 0.978
Yes 51 10/51 22/51
T stage T2 17 6/17 0.398 11/17 0.103
>T2 71 16/71 28/71
N stage N or N0 64 17/64 0.862 30/64 0.981
N1 24 5/24 9/24
Fuhrman grade <4 76 18/76 0.644 30/76 0.102
4 12 4/12 9/12
Leibovich score <6 41 9/41 0.244 17/41 0.275
6 47 13/47 22/47
IFN-a adjuvant therapy Yes 38 11/38 0.922 21/38 0.414
No 50 11/50 18/50
Nuclear FIH þ 31 4/31 0.048 10/31 0.032
 57 18/57 29/57
Cytoplasmic FIH þ 34 14/34 0.024 24/34 0.002
 54 8/54 15/54
Exclusive nuclear FIHþ 15 0/15 0.008 1/15 <0.001
Nuclear and cytoplasmic FIHþ 16 4/16 916/
Exclusive cytoplasmic FIHþ 18 10/18 15/18
Nuclear and cytoplasmic FIH 39 8/39 14/39
FIH Z factor-inhibiting hypoxia-inducible factor; IFN-a Z interferon-alpha; LARCC Z locally advanced renal cell carcinoma;
OS Z overall survival; PFS Z progression-free survival.
FIH expression in renal tumor 17heterodimer, HIF consists of two parts: a and b subunits.
Compared with the b subunit, which is steadily expressed in
the cell, the a subunit levels change constantly with rapid
upregulation and degradation [14]. Only when the twoTable 3 HR of PFS and OS between subgroups according
to the nuclear and cytoplasmic HIF expressions.
Group HR p
PFS
Nuclear and cytoplasmic FIH
negative expression
Reference,
HR Z 1
Nuclear and cytoplasmic FIH
expression
1.241 0.632
Exclusive nuclear FIH expression 0.153 0.07
Exclusive cytoplasmic FIH expression 2.876 0.005
OS
Nuclear and cytoplasmic FIH
negative expression
Reference,
HR Z 1
Nuclear and cytoplasmic FIH
expression
1.046 0.942
Exclusive nuclear FIH expression 0 0.961
Exclusive cytoplasmic FIH expression 2.799 0.034
FIH Z factor-inhibiting hypoxia-inducible factor; HR Z hazard
ratio; OS Z overall survival; PFS Z progression-free survival.subunits are combined, the transcriptional complex can be
activated fully to perform its transcription function [22].
The current research showed that the activity of Fe (II)
and 2-oxoglutarate-dependent dioxygenases under nor-
moxic conditions was regulated by at least two different
regulatory mechanisms. The oxygen-dependent degrada-
tion domain (part of the N-terminal transcriptional activa-
tion domain) of HIF-1a was hydroxylated by the PHDs
(PHD1, PHD2, and PHD3). This post-translational modifica-
tion allowed easy identification by the Von Hippel Lindau
protein, which ultimately resulted in degradation [23].
Meanwhile, the asparagine residue in C-terminal trans-
activation domain was hydroxylated by FIH, preventing it
from binding to the cofactor p300 [24]. These two mecha-
nisms often work in a complementary manner, thus
restricting HIF-1a activity to a minimum.
Activation of the two dioxygenases was dependent on
the presence of oxygen [25]. However, as the oxygen levels
decreased, the activity of both PHDs and FIH was affected,
leading to the accumulation of HIF-1a. Unlike the PHDs, FIH
has a higher affinity for oxygen, which means that FIH will
continue to function until severe hypoxia occurs [26]. This
phenomenon suggests that FIH may play a more vital role in
suppressing the HIF expression.
The proteins regulated by HIF were widely distributed in
epithelial cells with different expression patterns [27]. This
18 S. Deng et al.suggests that the HIF regulatory mechanism may cause
changes according to tumors in differentmicroenvironments.
Thus, the prognostic values of FIH are understandably diverse
in different tumors. Couvelard et al. [28] found that the
cytoplasmic FIH levels are significantly higher in malignant
pancreatic endocrine tumors (PETs) and PETs with lymph
node metastases. In addition, FIH stromal expression is
associated with a poor disease-free survival. Tan et al. [29]
found that FIH is widely expressed in invasive breast carci-
noma, and the absence of both nuclear and cytoplasmic FIH
expressions are an independent prognostic factor for a
shorter disease-free survival. Kroeze et al. [18] first reported
that low nuclear FIH expression is a significant independent
predictor for worse OS in ccRCC patients. However, nearly
half (46%)of thepatients included in this studyareearly-stage
RCC cases. Thus, there may be some limitations in their
conclusion.
In the current research, the expression of FIH and its
potential prognostic role in patients at high risk of acquiring
metastatic disease were analyzed. Unlike the report of
Kroeze et al. [18], expression of FIH was located in the
nucleus, the cytoplasm, or both compartments. The nu-
cleus expression rate of FIH was 35.2% (31/88) and the
cytoplasm expression rate was 38.6% (34/88). The signifi-
cance of FIH localization in tumor cells is yet to be identi-
fied fully. Tan et al. [29] proposed that cytoplasmic
translocation of FIH from nucleus may cause adverse con-
sequences. The results of their report are analogous to our
findings. According to the different subcellular locations,
FIH expression was first stratified into four categories as
follows: nuclear FIH positive expression group, nuclear FIH
negative expression group, cytoplasmic FIH positive
expression group, and cytoplasmic FIH negative expression
group. It was found that the nuclear negative expression
and positive cytoplasmic expression of FIH were predomi-
nately associated with shorter PFS and OS time. In order to
further verify the influence of subcellular localization, 88
cases were also stratified into four groups: exclusive nu-
clear FIH expression, nuclear and cytoplasmic FIH expres-
sion, exclusive cytoplasmic FIH expression, and nuclear and
cytoplasmic FIH negative expression. There was probably
some antagonistic relationship between the nuclear FIH
expression and cytoplasmic FIH expression and because
accompany cytoplasmic translocation of FIH from the nu-
cleus, the PFS and OS time have become shorter. To the
best of our knowledge, this is the first report demonstrating
the prognostic role of FIH in high-risk LARCC.
Strong relationships have been identified between HIF-1
and various tumors, including brain [30], ovary [31], lung
[32], esophageal [33], and so on. Moreover, one study
pointed out that the HIF-1 overexpression is related to
distant metastasis [34]. As a key regulator of HIF gene
expression, FIH may also be involved directly in metastasis.
In the present study, the nuclear negative expression or
positive cytoplasmic expression of FIH was found to be
associated with metastatic lesions. However, our data
failed to show any association in terms of the sites of the
metastases.
Although IFN-a adjuvant therapy was once considered as
the frontline postoperative treatment for metastatic RCC,
the unfortunate reality is that accumulated evidence
showed that the traditional treatment model has nocurative effects [35]. Of the 88 patients in the current
work, 38 received IFN-a as an adjuvant therapy; however,
no benefits were found in them with respect to PFS or OS.
Among those who received immunotherapy, surprisingly,
the nuclear negative expression of FIH was found to be
associated with a significant negative predictive value for
the effect of IFN-a on PFS (p Z 0.045). At present,
molecular-targeted therapy is recommended as the first-
line therapy in Europe and the USA [36]. However, this
pattern was associated with some adverse events, and no
long-term effect was observed. It is hoped that FIH can be
utilized in predicting prognosis with molecular-targeted
therapy, similar to its association with IFN therapy, to
avoid unnecessary usage of drugs.
The first prognostic nomogram after nephrectomy was
presented by Kattan et al. in 2001 [5]. UISS, SSIGN, and Lei-
bovich algorithm [5e7] are the most popular integrated
staging systems used currently to predict the outcome of
patients with ccRCC. However, of these systems, the
concordance rates for those that are based on the TNM clas-
sification range from60% to 85%only. In the current study, the
Leibovich scoring system was unable to show any predictive
role in high-risk LARCC. Although not widely used as a clinical
decisionafternephrectomy, thepredictive roleofbiomarkers
provided more meaningful information. In the present study,
the nuclear negative expression and positive cytoplasmic
expression of FIH were found to be associated with shorter
PFS and OS time. Therefore, FIH can be considered as an in-
dependent predictive factor for high-risk LARCC.Conclusion
For patients with high-risk LARCC, FIH can act as an inde-
pendent predictive factor for recurrence, distant meta-
static disease, and OS. However, the small sample size used
in this trial limits the applications of this study. Thus, a
prospective clinical trial is required to validate these pre-
dictive roles.Acknowledgments
The authors thank Professor Canhua Huang (Oncoproteo-
mics Group, The State Key Laboratory of Biotherapy,
Sichuan University) for his continuous support to this work.References
[1] Devesa SS, Silverman DT, McLaughlin JK, Brown CC,
Connelly RR, Fraumeni Jr JF. Comparison of the descriptive
epidemiology of urinary tract cancers. Cancer Causes Control
1990;1:133e41.
[2] Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C.
Epidemiologic and socioeconomic burden of metastatic renal
cell carcinoma (mRCC): a literature review. Cancer Treat Rev
2008;34:193e205.
[3] Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal
cell carcinoma 2005: new frontiers in staging, prognostication
and targeted molecular therapy. J Urol 2005;173:1853e62.
[4] Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance
after radical or partial nephrectomy for localized renal cell
FIH expression in renal tumor 19carcinoma and management of recurrent disease. Urol Clin
North Am 2003;30:843e52.
[5] Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A post-
operative prognostic nomogram for renal cell carcinoma. J
Urol 2001;166:63e7.
[6] Ficarra V, Novara G, Galfano A, Brunelli M, Cavalleri S,
Martignoni G, et al. The ’Stage, Size, Grade and Necrosis’
score is more accurate than the University of California Los
Angeles Integrated Staging System for predicting cancer-
specific survival in patients with clear cell renal cell carci-
noma. BJU Int 2009;103:165e70.
[7] LeibovichBC,BluteML,Cheville JC, LohseCM,Frank I, KwonED,
et al. Prediction of progression after radical nephrectomy for
patients with clear cell renal cell carcinoma: a stratification
tool for prospective clinical trials. Cancer 2003;97:1663e71.
[8] Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma.
World J Urol 2010;28:319e27.
[9] Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, et al. He-
patocellular carcinoma risk prediction model for the general
population: the predictive power of transaminases. J Natl
Cancer Inst 2012;104:1599e611.
[10] Hong SY, Cho DS, Kim SI, Ahn HS, Kim SJ. Prostate-specific
antigen nadir and time to prostate-specific antigen nadir
following maximal androgen blockade independently predict
prognosis in patients with metastatic prostate cancer. Korean
J Urol 2012;53:607e13.
[11] Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I,
et al. Predictive value of baseline serum vascular endothelial
growth factor and neutrophil gelatinase-associated lipocalin
in advanced kidney cancer patients receiving sunitinib. Kidney
Int 2010;77:809e15.
[12] Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H,
Webster WS, et al. Costimulatory B7-H1 in renal cell carci-
noma patients: indicator of tumor aggressiveness and poten-
tial therapeutic target. Proc Natl Acad Sci U S A 2004;101:
17174e9.
[13] Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molec-
ular markers in the diagnosis and therapy of renal cell carci-
noma. Urology 2005;66:1e9.
[14] Harris AL. Hypoxiada key regulatory factor in tumour growth.
Nat Rev Cancer 2002;2:38e47.
[15] Bruick RK, McKnight SL. A conserved family of prolyl-4-
hydroxylases that modify HIF. Science 2001;294:1337e40.
[16] Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML,
Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that
regulates the transcriptional activity of hypoxia-inducible
factor. Genes Dev 2002;16:1466e71.
[17] Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM.
The oxygen sensor factor-inhibiting hypoxia-inducible factor-1
controls expression of distinct genes through the bifunctional
transcriptional character of hypoxia-inducible factor-1alpha.
Cancer Res 2006;66:3688e98.
[18] Kroeze SG, Vermaat JS, van Brussel A, van Melick HH,
Voest EE, Jonges TG, et al. Expression of nuclear FIH inde-
pendently predicts overall survival of clear cell renal cell
carcinoma patients. Eur J Cancer 2010;46:3375e82.
[19] Dvorak HF. Vascular permeability factor/vascular endothelial
growth factor: a critical cytokine in tumor angiogenesis and a
potential target for diagnosis and therapy. J Clin Oncol 2002;20:
4368e80.
[20] Folkman J. Fighting cancer by attacking its blood supply. Sci
Am 1996;275:150e4.[21] Semenza GL. Regulation of mammalian O2 homeostasis by
hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:
551e78.
[22] Brugarolas J. Renal-cell carcinomadmolecular pathways and
therapies. N Engl J Med 2007;356:185e7.
[23] Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al.
HIFalpha targeted for VHL-mediated destruction by proline
hydroxylation: implications for O2 sensing. Science 2001;292:
464e8.
[24] Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML.
Asparagine hydroxylation of the HIF transactivation domain a
hypoxic switch. Science 2002;295:858e61.
[25] Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN,
Welford RW, et al. Hypoxia-inducible factor (HIF) asparagine
hydroxylase is identical to factor inhibiting HIF (FIH) and is
related to the cupin structural family. J Biol Chem 2002;277:
26351e5.
[26] Koivunen P, Hirsila¨ M, Gu¨nzler V, Kivirikko KI, Myllyharju J.
Catalytic properties of the asparaginyl hydroxylase (FIH) in
the oxygen sensing pathway are distinct from those of its
prolyl 4-hydroxylases. J Biol Chem 2004;279:9899e904.
[27] Lieb ME, Menzies K, Moschella MC, Ni R, Taubman MB.
Mammalian EGLN genes have distinct patterns of mRNA
expression and regulation. Biochem Cell Biol 2002;80:421e6.
[28] Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K,
Pezzella F, et al. Overexpression of the oxygen sensors PHD-1,
PHD-2, PHD-3, and FIH is associated with tumor aggressiveness
in pancreatic endocrine tumors. Clin Cancer Res 2008;14:
6634e9.
[29] Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, et al.
Cytoplasmic location of factor-inhibiting hypoxia-inducible
factor is associated with an enhanced hypoxic response and a
shorter survival in invasive breast cancer. Breast Cancer Res
2007;9:R89.
[30] Birner P, Gatterbauer B, Oberhuber G, Schindl M, Ro¨ssler K,
Prodinger A, et al. Expression of hypoxia-inducible factor-1
alpha in oligodendrogliomas: its impact on prognosis and on
neoangiogenesis. Cancer 2001;92:165e71.
[31] Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G.
Expression of hypoxia-inducible factor 1alpha in epithelial
ovarian tumors: its impact on prognosis and on response to
chemotherapy. Clin Cancer Res 2001;7:1661e8.
[32] Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K,
Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha
and 2 alpha in operable non-small cell lung cancer to angio-
genic/molecular profile of tumours and survival. Br J Cancer
2001;85:881e90.
[33] Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y,
et al. Overexpression of hypoxia-inducible-factor 1alpha(HIF-
1alpha) in oesophageal squamous cell carcinoma correlates
with lymph node metastasis and pathologic stage. Br J Cancer
2003;89:1042e7.
[34] Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L,
Haddad O, Lavaut MN, et al. Overexpression of hypoxia-
inducible factor HIF-1alpha predicts early relapse in breast
cancer: retrospective study in a series of 745 patients. Int J
Cancer 2005;116:734e9.
[35] Vuky J, Motzer RJ. Cytokine therapy in renal cell cancer. Urol
Oncol 2000;5:249e57.
[36] Bellmunt J, Guix M. The medical management of metastatic
renal cell carcinoma: integrating new guidelines and recom-
mendations. BJU Int 2009;103:572e7.
